Viewing Study NCT06453902


Ignite Creation Date: 2025-12-25 @ 4:06 AM
Ignite Modification Date: 2025-12-26 @ 3:02 AM
Study NCT ID: NCT06453902
Status: RECRUITING
Last Update Posted: 2025-02-21
First Post: 2024-05-28
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Sponsor: Shenzhen TargetRx, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module